OBS Pakistan Pvt. Ltd.

obs.com.pk

The OBS Group is one of Pakistan’s leading corporations in the healthcare segment with presence in Pakistan and Sri Lanka. OBS commenced operations in 1963 and became a name associated with quality medicine throughout Pakistan in 2006 after entering into a strategic alliance with Organon (part of Akzo Nobel). Since then, OBS has fostered strategic alliances with many reputable international firms including Organon, Merck & Co Inc, USA, Schering Plough, AstraZeneca, Mylan USA, Vifor Switzerland and Santen Pharma Japan.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

AIKIDO PHARMA REPORTS IMPROVED MANUFACTURING PROCESS AND NEW UNITED STATES PATENT FOR PANCREATIC DRUG

AIkido Pharma Inc. | March 04, 2022

news image

AIkido Pharma Inc.reported an improvement in the manufacturing process for its pancreatic cancer drug, DHA-dFdC, licensed from the University of Texas at Austin. The Company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug. With respect to manufacturing process, the Company reported the successful development of a new means for the scaled pro...

Read More

PHARMACY MARKET, PHARMA TECH

PRESCRYPTIVE HEALTH PARTNERS WITH LILLY ON FIRST-TO-MARKET VALUE-BASED PROGRAM TO STABILIZE INSULIN PRICING

Prescryptive Health | December 16, 2022

news image

Prescryptive Health, a healthcare technology company on a mission to rewrite the script for the U.S. pharmaceutical market, today announced a partnership with Eli Lilly and Company on a new and first-to-market subscription model to help lower costs for people who pay for their Lilly insulin through their employer-sponsored benefits. Through a flat, per-member, per-month subscription fee, employers can offer insulin to their employees with predictable, affordable, and transparent costs. This uniq...

Read More

Business Insights

ENABLE INJECTIONS ENHANCES BOARD WITH ADDITION OF JOHN DEFORD, PH.D.

Enable Injections, Inc. | August 12, 2022

news image

Enable Injections, Inc. a company developing and manufacturing the enFuse® platform of investigational wearable drug delivery systems, is pleased to announce the appointment of John DeFord, Ph.D. to the company's Board of Directors, effective July 29, 2022. Enable Injections' enFuse is an innovative drug delivery technology designed to subcutaneously (SC) deliver large volumes of up to 50mL for a wide range of therapies and diseases, dedicated to improving the patient ...

Read More

MARINUS PHARMACEUTICALS EARNS RARE PEDIATRIC DISEASE DESIGNATION FROM FDA FOR GANAXOLONE TREATING CDKL5 DEFICIENCY DISORDER (CDD)

Marinus Pharmaceuticals | July 31, 2020

news image

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s product candidate ganaxolone for the treatment of CDKL5 deficiency disorder (CDD), a rare refractory form of pediatric epilepsy. “We are pleased that ganaxolone has received Rare Pediatric Dis...

Read More
news image

Pharmacy Market

AIKIDO PHARMA REPORTS IMPROVED MANUFACTURING PROCESS AND NEW UNITED STATES PATENT FOR PANCREATIC DRUG

AIkido Pharma Inc. | March 04, 2022

AIkido Pharma Inc.reported an improvement in the manufacturing process for its pancreatic cancer drug, DHA-dFdC, licensed from the University of Texas at Austin. The Company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug. With respect to manufacturing process, the Company reported the successful development of a new means for the scaled pro...

Read More
news image

PHARMACY MARKET, PHARMA TECH

PRESCRYPTIVE HEALTH PARTNERS WITH LILLY ON FIRST-TO-MARKET VALUE-BASED PROGRAM TO STABILIZE INSULIN PRICING

Prescryptive Health | December 16, 2022

Prescryptive Health, a healthcare technology company on a mission to rewrite the script for the U.S. pharmaceutical market, today announced a partnership with Eli Lilly and Company on a new and first-to-market subscription model to help lower costs for people who pay for their Lilly insulin through their employer-sponsored benefits. Through a flat, per-member, per-month subscription fee, employers can offer insulin to their employees with predictable, affordable, and transparent costs. This uniq...

Read More
news image

Business Insights

ENABLE INJECTIONS ENHANCES BOARD WITH ADDITION OF JOHN DEFORD, PH.D.

Enable Injections, Inc. | August 12, 2022

Enable Injections, Inc. a company developing and manufacturing the enFuse® platform of investigational wearable drug delivery systems, is pleased to announce the appointment of John DeFord, Ph.D. to the company's Board of Directors, effective July 29, 2022. Enable Injections' enFuse is an innovative drug delivery technology designed to subcutaneously (SC) deliver large volumes of up to 50mL for a wide range of therapies and diseases, dedicated to improving the patient ...

Read More
news image

MARINUS PHARMACEUTICALS EARNS RARE PEDIATRIC DISEASE DESIGNATION FROM FDA FOR GANAXOLONE TREATING CDKL5 DEFICIENCY DISORDER (CDD)

Marinus Pharmaceuticals | July 31, 2020

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s product candidate ganaxolone for the treatment of CDKL5 deficiency disorder (CDD), a rare refractory form of pediatric epilepsy. “We are pleased that ganaxolone has received Rare Pediatric Dis...

Read More